Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX 1503 in moderate to severe acne vulgaris
NCT03573518Phase 2Completed
- Sponsor
- Botanix Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Aug 2019
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of BTX 1503 in acne vulgaris (5 arms), sponsored by Botanix Pharmaceuticals. Primary endpoint: Safety as Measured by Reported Adverse Events at Day 84. Started Jun 2018; status: completed.
02
Drugs
BTX 1503
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03573518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573518.